Details for Patent: 8,114,831

Title:	Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Abstract:	A method of treatment of inflamed, pre-cancerous or cancerous tissue or polyps in a mammalian subject is disclosed. The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps.
Inventor(s):	Shailubhai; Kunwar (Audobon, PA), Nikiforovich; Gregory (St. Louis, MO), Jacob; Gary S. (New York, NY)
Assignee:	Synergy Pharmaceuticals Inc. (New York, NY)
Filing Date:	Apr 20, 2010
Application Number:	12/763,707
Claims:	1. A method for treating inflammatory bowel disease in a patient comprising administering to said patient an effective dosage of a peptide consisting of SEQ ID NO:8, wherein said peptide is a (4,12; 7,15) bicycle and wherein said peptide binds a guanylate cyclase receptor and induces cGMP production. 2. Themethod of claim 1, wherein said peptide consists of the sequence of SEQ ID NO:20. 3. The method of claim 1, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and Crohn's disease. 4. The method of claim 1, further comprising administering to said patient an effective dose of an inhibitor of cGMP-dependent phosphodiesterase either concurrently or sequentially with said guanylate cyclase receptor agonist, wherein said inhibitor of cGMP-dependent phosphodiesterase is selected from the group consisting of sulindac sulfone, zaprinast, and motapizone.